Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Xadago
Xadago 50 mg film-coated tablets Xadago 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-125742 · Präparat HOS-096139
Safinamide may transiently inhibit BCRP in vitro. In drug-drug-interaction studies in human, a weak
interaction was observed with rosuvastatin (AUC increase between 1.25 and 2.00 fold) but no
significant interaction was found with diclofenac.
It is recommended to monitor patients when safinamide is taken with medicinal products that are
BCRP substrates (e.g., rosuvastatin, pitavastatin, pravastatin, ciprofloxacin, methotrexate, topotecan,
diclofenac or glyburide) and to refer to their SmPCs to determine if a dose adjustment is needed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diclofenac (HOS-085903) ciprofloxacin (HOS-085177) rosuvastatin (HOS-086307) glyburide (HOS-109273) topotecan (HOS-086047) pravastatin (HOS-086306) methotrexate (HOS-087522) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-09T12:57:00Z · SHA-256 48b01ba5b1179c2ba1e43605dbb52f4115246d6aa2dd76fd1814d41eff2382ed · Passage 6209a05ebfa51ab92a4802251e36995d5753c8d309a1724a8ad0591933fc6d76 · Zeichen 2416–2956 im Abschnitt
Wechselwirkungen · Mekinist
Mekinist 0.5 mg film-coated tablets Mekinist 2 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-127984 · Präparat HOS-096501
Based on in vitro and in vivo data, trametinib is unlikely to significantly affect the pharmacokinetics of
other medicinal products via interaction with CYP enzymes or transporters (see section 5.2).
Trametinib may result in transient inhibition of BCRP substrates (e.g. pitavastatin) in the gut, which
may be minimised with staggered dosing (2 hours apart) of these agents and trametinib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-22T14:43:00Z · SHA-256 e9740c279dc56efc8c0abe9928f9fd6e69edfd7192baf6df7f5be09736566a55 · Passage 1fba02de12d3d4088ca4749d4b2e3d8881d1ca257c1c93c13909c5e1d624727b · Zeichen 814–1203 im Abschnitt
Wechselwirkungen · Sivextro
Sivextro 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-130234 · Präparat HOS-096879
Breast cancer resistance protein transporter inhibition
In a clinical study comparing the single dose (10 mg) pharmacokinetics of rosuvastatin (Breast Cancer
Resistant Protein [BCRP] substrate, see section 5.2) alone or in combination with tedizolid phosphate
(once-daily 200 mg oral dose), rosuvastatin AUC and Cmax increased by approximately 70% and 55%,
respectively, when co-administered with tedizolid phosphate. Therefore, orally administered tedizolid
phosphate can result in inhibition of BCRP at the intestinal level. If possible, an interruption of the co-
administered BCRP substrate medicinal product (such as imatinib, lapatinib, methotrexate,
pitavastatin, rosuvastatin, sulfasalazine, and topotecan) should be considered during the 6 days of
treatment with oral tedizolid phosphate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfasalazine (HOS-089673) rosuvastatin (HOS-086307) imatinib (HOS-110212) lapatinib (HOS-122565) topotecan (HOS-086047) methotrexate (HOS-087522) tedizolid phosphate (HOS-130230) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T12:22:00Z · SHA-256 67755293d17b65838d18c0065efbf6826bb5cdd2698a851f617dd402e701dbd8 · Passage 9edcbf20c0dd1a9a2297e953e0bad5b473fc9fbc3573e6faff13cba7d926488e · Zeichen 69–866 im Abschnitt
Wechselwirkungen · Sivextro
Sivextro 200 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 18
HOS-130262 · Präparat HOS-096879
Breast cancer resistance protein transporter inhibition
In a clinical study comparing the single dose (10 mg) pharmacokinetics of rosuvastatin (Breast Cancer
Resistant Protein [BCRP] substrate, see section 5.2) alone or in combination with tedizolid phosphate
(once-daily 200 mg oral dose), rosuvastatin AUC and Cmax increased by approximately 70% and 55%,
respectively, when co-administered with tedizolid phosphate. Therefore, orally administered tedizolid
phosphate can result in inhibition of BCRP at the intestinal level. If possible, an interruption of the co-
administered BCRP substrate medicinal product (such as imatinib, lapatinib, methotrexate,
pitavastatin, rosuvastatin, sulfasalazine, and topotecan) should be considered during the 6 days of
treatment with oral tedizolid phosphate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfasalazine (HOS-089673) rosuvastatin (HOS-086307) imatinib (HOS-110212) lapatinib (HOS-122565) topotecan (HOS-086047) methotrexate (HOS-087522) tedizolid phosphate (HOS-130230) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T12:22:00Z · SHA-256 67755293d17b65838d18c0065efbf6826bb5cdd2698a851f617dd402e701dbd8 · Passage 9edcbf20c0dd1a9a2297e953e0bad5b473fc9fbc3573e6faff13cba7d926488e · Zeichen 69–866 im Abschnitt
Wechselwirkungen · Sivextro
Sivextro 245 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 34–35
HOS-130287 · Präparat HOS-096879
34
Breast cancer resistance protein transporter inhibition
In a clinical study comparing the single dose (10 mg) pharmacokinetics of rosuvastatin (Breast Cancer
Resistant Protein [BCRP] substrate, see section 5.2) alone or in combination with tedizolid phosphate
(once-daily 200 mg oral dose), rosuvastatin AUC and Cmax increased by approximately 70% and 55%,
respectively, when co-administered with tedizolid phosphate. Therefore, orally administered tedizolid
phosphate can result in inhibition of BCRP at the intestinal level. If possible, an interruption of the co-
administered BCRP substrate medicinal product (such as imatinib, lapatinib, methotrexate,
pitavastatin, rosuvastatin, sulfasalazine, and topotecan) should be considered during the 6 days of
treatment with oral tedizolid phosphate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfasalazine (HOS-089673) rosuvastatin (HOS-086307) imatinib (HOS-110212) lapatinib (HOS-122565) topotecan (HOS-086047) methotrexate (HOS-087522) tedizolid phosphate (HOS-130230) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T12:22:00Z · SHA-256 67755293d17b65838d18c0065efbf6826bb5cdd2698a851f617dd402e701dbd8 · Passage 33d48cf21b8551e7417562913732d62f09e164e6df806063e3727208c40ad2d5 · Zeichen 122–923 im Abschnitt
Wechselwirkungen · Zydelig
Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-132108 · Präparat HOS-097192
Atorvastatin ↑ serum concentrations Clinical monitoring is recommended
and a lower starting dose of
atorvastatin may be considered.
Alternatively, switching to pravastatin,
rosuvastatin, or pitavastatin may be
considered.
IMMUNOSUPPRESSANTS
Ciclosporin, sirolimus, ↑ serum concentrations Therapeutic monitoring is
tacrolimus recommended.
INHALED BETA AGONIST
Salmeterol ↑ serum concentrations Concurrent administration of
salmeterol and idelalisib is not
recommended. The combination may
result in increased risk of
cardiovascular adverse events
associated with salmeterol, including
QT prolongation, palpitations, and
sinus tachycardia.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) rosuvastatin (HOS-086307) salmeterol (HOS-086285) tacrolimus (HOS-085202) sirolimus (HOS-085172) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-21T17:52:00Z · SHA-256 f55f90ba278a87ef1c8e7162344ed4bd66ac7180deaf4c8fda3eca5bbf8e87e5 · Passage 605a8be7dd70dff78b919a26f1676d15c94c8048045977153eff24af0e81463e · Zeichen 9857–11294 im Abschnitt
Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18
HOS-134017 · Präparat HOS-097520
Genvoya is not expected to have a
clinically relevant effect on plasma
concentrations of the active
metabolite of prasugrel.
INHALED BETA AGONIST
Salmeterol Interaction not studied with any of Concurrent administration of
the components of Genvoya. salmeterol and Genvoya is not
recommended.
Co-administration with Genvoya
may result in increased plasma
concentrations of salmeterol, which
is associated with the potential for
serious or life-threatening adverse
reactions.
HMG CO-A REDUCTASE INHIBITORS
Rosuvastatin (10 mg single dose)/ Elvitegravir: Concentrations of rosuvastatin are
Elvitegravir (150 mg once daily)/ AUC: ↔ transiently increased when
Cobicistat (150 mg once daily) Cmin: ↔ administered with elvitegravir and
Cmax: ↔ cobicistat. Dose modifications are
not necessary when rosuvastatin is
Rosuvastatin: administered in combination with
AUC: ↑ 38% Genvoya.
Cmin: N/A
Cmax: ↑ 89%
Atorvastatin (10 mg single Atorvastatin: Concentrations of atorvastatin are
dose)/Elvitegravir (150 mg once AUC: ↑ 160% increased when co-administered
daily)/Cobicistat (150 mg once Cmin: N/A with elvitegravir and cobicistat.
daily)/Emtricitabine (200 mg once Cmax: ↑ 132% Start with the lowest possible dose
daily)/Tenofovir alafenamide of atorvastatin with careful
(10 mg once daily) Elvitegravir: monitoring upon co-administration
AUC: ↔ with Genvoya.
Cmin: ↔
Cmax: ↔
Pitavastatin Interaction not studied with any of Caution should be exercised when
the components of Genvoya. co-administering Genvoya with
pitavastatin.
Concentrations of pitavastatin may
be increased when administered
with elvitegravir and cobicistat.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) rosuvastatin (HOS-086307) salmeterol (HOS-086285) prasugrel (HOS-112066) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 7e31f3eeee923ea18ba80fdd3f8b3ff8a1b59702bd502d3e1a8df30b4a2beea0 · Zeichen 38274–41404 im Abschnitt
Wechselwirkungen · Tookad
TOOKAD 183 mg powder for solution for injection TOOKAD 366 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 6
HOS-136010 · Präparat HOS-097808
The magnitude of interaction has not been investigated clinically but a transient increase in the plasma
concentration of co-administered substrates of OATP1B1 and OATP1B3 cannot be ruled out. The use
of medicinal products that are substrates of OATP1B1 or OATP1B3 (repaglinide, atorvastatin,
pitavastatin, pravastatin, rosuvastatin, simvastatin, bosentan, glyburide) for which
concentration-dependent serious adverse reactions have been observed should be avoided on the day
of TOOKAD infusion and for at least 24 hours after administration. Co-administration should be done
with caution and close monitoring is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) glyburide (HOS-109273) bosentan (HOS-086291) repaglinide (HOS-086935) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-12-07T01:00:00Z · SHA-256 86ab6205066703c9c0efe5f9fcb6f836848dd067cf287be0e096ac7a8110e9b4 · Passage 848adb8ccf0775b284b88bfbe37ae01fbd096234720d95b4412fd63279d94101 · Zeichen 218–843 im Abschnitt
Wechselwirkungen · Kisqali
Kisqali 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-136232 · Präparat HOS-097860
In vitro evaluations indicated that ribociclib has a potential to inhibit the activities of drug transporters
P-gp, BCRP, OATP1B1/1B3, OCT1, OCT2, MATE1 and BSEP. Caution and monitoring for toxicity
are advised during concomitant treatment with sensitive substrates of these transporters which exhibit
a narrow therapeutic index, including but not limited to digoxin, pitavastatin, pravastatin, rosuvastatin
and metformin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) digoxin (HOS-086172) metformin (HOS-091032) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-19T11:22:00Z · SHA-256 808e9743b462916472557a0fc0a032e5a4cdf4c2e48d8fd0f992823e92cc05c1 · Passage 75a72466d51ecf0697de8b642c0adae193569e5fafdd5c96025e95dc6a616927 · Zeichen 6497–6919 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-138493 · Präparat HOS-098200
14
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Based on theoretical considerations Co-administration of Symtuza
bosentan is expected to decrease and bosentan is not
darunavir and/or cobicistat plasma recommended.
concentrations.
(CYP3A induction)
Symtuza is expected to increase
bosentan plasma concentrations.
(CYP3A inhibition)
ERGOT DERIVATIVES
e.g. Based on theoretical considerations Co-administration of Symtuza
Dihydroergotamine DRV/COBI may increase ergot and ergot derivatives is
Ergometrine derivative exposure. contraindicated (see section 4.3).
Ergotamine
Methylergonovine
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A inhibitors
Elbasvir/grazoprevir Based on theoretical considerations Concomitant use of Symtuza with
Symtuza may increase the elbasvir/grazoprevir is
exposure to grazoprevir. contraindicated (see section 4.3).
(OATP1B and CYP3A inhibition)
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to
DRV/COBI may increase the co-administer Symtuza with
exposure to glecaprevir and glecaprevir/pibrentasvir.
pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
Daclatasvir Based on theoretical Symtuza and sofosbuvir,
Ledipasvir considerations, no clinically sofosbuvir/ledipasvir, or
Sofosbuvir relevant interaction is expected. daclatasvir can be used
concomitantly without dose
adjustment
Herbal products
St. John’s Wort (Hypericum
Based on theoretical consideration, The concomitant use of Symtuza
perforatum) St. John’s Wort may substantially with these medicinal products is
decrease DRV/COBI (CYP3A4 contraindicated (see section 4.3).
induction) and TAF exposures.
(P-gp induction)
HMG CO-A REDUCTASE INHIBITORS
Atorvastatin Atorvastatin (10 mg once daily): Concomitant use of a HMG CoA
Fluvastatin atorvastatin AUC ↑ 290% reductase inhibitor and Symtuza
Pitavastatin atorvastatin Cmax ↑ 319% may increase plasma
Pravastatin atorvastatin Cmin ND concentrations of the lipid
Rosuvastatin lowering agent, which may lead
Rosuvastatin (10 mg once daily): to adverse reactions such as
rosuvastatin AUC ↑ 93% myopathy.
rosuvastatin Cmax ↑ 277% When administration of
rosuvastatin Cmin ND HMG CoA reductase inhibitors
and Symtuza is desired, it is
Based on theoretical considerations recommended to start with the
DRV/COBI is expected to increase lowest dose and titrate up to the
the plasma concentrations of desired clinical effect while
fluvastatin, pitavastatin, monitoring for safety.
pravastatin, lovastatin and
Lovastatin simvastatin. Concomitant use of Symtuza with
Simvastatin (CYP3A inhibition and/or lovastatin and simvastatin is
transport) contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) methylergonovine (HOS-086155) daclatasvir (HOS-119742) sofosbuvir (HOS-108928) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) ledipasvir (HOS-110493) simvastatin (HOS-086158) rosuvastatin (HOS-086307) glecaprevir (HOS-086297) fluvastatin (HOS-086305) hepatitis C virus (HOS-108813) lead (HOS-085592) grazoprevir (HOS-108815) ergotamine (HOS-086154) bosentan (HOS-086291) dihydroergotamine (HOS-086152) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 7dedc11142e46d7502bc7e251f11ffb3c178eac67ce8ce16fb9ccc902e5f3904 · Zeichen 28527–32949 im Abschnitt
Wechselwirkungen · Maviret
Maviret 100 mg/40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-139039 · Präparat HOS-098268
8
Lovastatin ↑ lovastatin ↔ 1.70 -- Co-administration
10 mg once daily (1.40, is not
2.06) recommended. If
(Inhibition of ↑ lovastatin 5.73 4.10 -- used, lovastatin
OATP1B1/3, P- acid (4.65, 7.07) (3.45, should not exceed
gp, BCRP) 4.87) a dose of 20
mg/day and
patients should be
monitored.
Pravastatin ↑ pravastatin 2.23 2.30 -- Caution is
10 mg once daily (1.87, 2.65) (1.91, recommended.
2.76) Pravastatin dose
(Inhibition of should not exceed
OATP1B1/3) 20 mg per day
Rosuvastatin ↑ 5.62 2.15 -- and rosuvastatin
5 mg once daily rosuvastatin (4.80, 6.59) (1.88, dose should not
2.46) exceed 5 mg per
(Inhibition of day.
OATP1B1/3,
BCRP)
Fluvastatin, Not studied. Interactions with
Pitavastatin Expected: ↑ fluvastatin and ↑ pitavastatin fluvastatin and
pitavastatin are
likely and caution
is recommended
during the
combination. A
low dose of the
statin is
recommended at
the initiation of
the DAA
treatment.
IMMUNOSUPPRESSANTS
Ciclosporin ↑ glecaprevirc 1.30 1.37 1.34 Maviret is not
100 mg single (0.95, 1.78) (1.13, (1.12, 1.60) recommended for
dose 1.66) use in patients
↑ pibrentasvir ↔ ↔ 1.26 requiring stable
(1.15, 1.37) ciclosporin doses
Ciclosporin ↑ glecaprevir 4.51 5.08 -- > 100 mg per day.
400 mg single (3.63, 6.05) (4.11, If the combination
dose 6.29) is unavoidable,
↑ pibrentasvir ↔ 1.93 -- use can be
(1.78, considered if the
2.09) benefit outweighs
the risk with a
close clinical
monitoring.
Tacrolimus ↑ tacrolimus 1.50 1.45 -- The combination
1 mg single dose (1.24, 1.82) (1.24, of Maviret with
1.70) tacrolimus should
(CYP3A4 and P- ↔ ↔ ↔ ↔ be used with
gp inhibition) glecaprevir caution. Increase
↔ ↔ ↔ ↔ of tacrolimus
pibrentasvir exposure is
expected.
Therefore, a
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) tacrolimus (HOS-085202) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-15T12:56:00Z · SHA-256 225c0ba8f2354e64e1131849dc7b6e23a86b099b858b5f9e8bda200a3bdf07cd · Passage 367b753680457b545e8392989af21731cbb002f8b6bc1081e4d022c9c01efc84 · Zeichen 15500–20605 im Abschnitt
Wechselwirkungen · Maviret
Maviret 50 mg/20 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 34–35
HOS-139093 · Präparat HOS-098268
34
HCV-ANTIVIRAL AGENTS
Sofosbuvir ↑ sofosbuvir 1.66 2.25 -- No dose adjustment
400 mg single dose (1.23, 2.22) (1.86, 2.72) is required.
↑ GS- ↔ ↔ 1.85
(P-gp/BCRP 331007 (1.67, 2.04)
inhibition) ↔ ↔ ↔ ↔
glecaprevir
↔ ↔ ↔ ↔
pibrentasvir
HMG-COA REDUCTASE INHIBITORS
Atorvastatin ↑ 22.0 8.28 -- Co-administration
10 mg once daily atorvastatin (16.4, 29.5) (6.06, 11.3) with atorvastatin and
simvastatin is
(Inhibition of contraindicated (see
OATP1B1/3, P-gp, section 4.3).
BCRP, CYP3A)
Simvastatin ↑ 1.99 2.32 --
5 mg once daily simvastatin (1.60, 2.48) (1.93, 2.79)
↑ 10.7 4.48 --
(Inhibition of simvastatin (7.88, 14.6) (3.11, 6.46)
OATP1B1/3, P-gp, acid
BCRP)
Lovastatin ↑ lovastatin ↔ 1.70 -- Co-administration is
10 mg once daily (1.40, 2.06) not recommended. If
↑ lovastatin 5.73 4.10 -- used, lovastatin
(Inhibition of acid (4.65, 7.07) (3.45, 4.87) should not exceed a
OATP1B1/3, P-gp, dose of 20 mg/day
BCRP) and patients should
be monitored.
Pravastatin ↑ pravastatin 2.23 2.30 -- Caution is
10 mg once daily (1.87, 2.65) (1.91, 2.76) recommended.
Pravastatin dose
(Inhibition of should not exceed
OATP1B1/3) 20 mg per day and
Rosuvastatin ↑ 5.62 2.15 -- rosuvastatin dose
5 mg once daily rosuvastatin (4.80, 6.59) (1.88, 2.46) should not exceed
5 mg per day.
(Inhibition of
OATP1B1/3,
BCRP)
Fluvastatin, Not studied. Interactions with
Pitavastatin Expected: ↑ fluvastatin and ↑ pitavastatin fluvastatin and
pitavastatin are
likely and caution is
recommended
during the
combination. A low
dose of the statin is
recommended at the
initiation of the
DAA treatment.
IMMUNOSUPPRESSANTS
Ciclosporin ↑ 1.30 1.37 1.34 Maviret is not
100 mg single dose glecaprevirc (0.95, 1.78) (1.13, 1.66) (1.12, 1.60) recommended for
↑ ↔ ↔ 1.26 use in patients
pibrentasvir (1.15, 1.37) requiring stable
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-15T12:56:00Z · SHA-256 225c0ba8f2354e64e1131849dc7b6e23a86b099b858b5f9e8bda200a3bdf07cd · Passage 07a1b621c990667394265e7af7d190b4e25e101150b99a5276f832859a7084c4 · Zeichen 12395–16855 im Abschnitt
Gegenanzeigen · Prevymis
PREVYMIS 240 mg film-coated tablets PREVYMIS 480 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 5
HOS-139768 · Präparat HOS-098408
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Concomitant administration with pimozide (see sections 4.4 and 4.5).
Concomitant administration with ergot alkaloids (see sections 4.4 and 4.5).
Concomitant administration with St. John’s wort (Hypericum perforatum) (see section 4.5).
When letermovir is combined with cyclosporine:
• Concomitant use of dabigatran, atorvastatin, simvastatin, rosuvastatin or pitavastatin is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) dabigatran (HOS-112096) ergot alkaloids (HOS-108807) pimozide (HOS-085600) cyclosporine (HOS-084512) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 517b81b5d1d5ee859357c149478d73102623a1d50cf1c70d308703e6f69e68bf · Zeichen 0–510 im Abschnitt
Gegenanzeigen · Prevymis
PREVYMIS 240 mg concentrate for solution for infusion PREVYMIS 480 mg concentrate for solution for infusion · Abschnitt 4.3 · PDF-Seite 37
HOS-139845 · Präparat HOS-098408
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Concomitant administration with pimozide (see sections 4.4 and 4.5).
Concomitant administration with ergot alkaloids (see sections 4.4 and 4.5).
Concomitant administration with St. John’s wort (Hypericum perforatum) (see section 4.5).
When letermovir is combined with cyclosporine:
• Concomitant use of dabigatran, atorvastatin, simvastatin, rosuvastatin or pitavastatin is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) dabigatran (HOS-112096) ergot alkaloids (HOS-108807) pimozide (HOS-085600) cyclosporine (HOS-084512) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 517b81b5d1d5ee859357c149478d73102623a1d50cf1c70d308703e6f69e68bf · Zeichen 0–510 im Abschnitt
Gegenanzeigen · Prevymis
PREVYMIS 20 mg granules in sachet PREVYMIS 120 mg granules in sachet · Abschnitt 4.3 · PDF-Seite 71
HOS-139912 · Präparat HOS-098408
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Concomitant administration with pimozide (see sections 4.4 and 4.5).
Concomitant administration with ergot alkaloids (see sections 4.4 and 4.5).
Concomitant administration with St. John’s wort (Hypericum perforatum) (see section 4.5).
When letermovir is combined with cyclosporine:
• Concomitant use of dabigatran, atorvastatin, simvastatin, rosuvastatin or pitavastatin is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) dabigatran (HOS-112096) ergot alkaloids (HOS-108807) pimozide (HOS-085600) cyclosporine (HOS-084512) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 517b81b5d1d5ee859357c149478d73102623a1d50cf1c70d308703e6f69e68bf · Zeichen 0–510 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 240 mg film-coated tablets PREVYMIS 480 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-139812 · Präparat HOS-098408
↑ or ↓ efavirenz
(CYP2B6 inhibition or
induction)
etravirine, Interaction not studied. These antivirals may decrease plasma
nevirapine, ritonavir, Expected: concentrations of letermovir.
lopinavir ↓ letermovir Co-administration of letermovir with these
antivirals is not recommended.
(P-gp/UGT induction)
HMG-CoA reductase inhibitors
atorvastatin‡ ↑ atorvastatin Statin-associated adverse events such as
(20 mg single dose)/ AUC 3.29 (2.84, 3.82) myopathy should be closely monitored.
letermovir (480 mg Cmax 2.17 (1.76, 2.67) The dose of atorvastatin should not exceed
daily) 20 mg daily when co-administered with
(CYP3A, OATP1B1/3 letermovir #.
inhibition)
Although not studied, when letermovir is
co-administered with cyclosporine, the
magnitude of the increase in atorvastatin
plasma concentrations is expected to be
greater than with letermovir alone.
When letermovir is co-administered with
cyclosporine, atorvastatin is
contraindicated.
simvastatin, Interaction not studied. Letermovir may substantially increase
pitavastatin, Expected: plasma concentrations of these statins.
rosuvastatin ↑ HMG-CoA reductase Concomitant use is not recommended with
inhibitors letermovir alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) etravirine (HOS-088088) efavirenz (HOS-087947) nevirapine (HOS-088064) ritonavir (HOS-084521) cyclosporine (HOS-084512) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage de2fe055110e3584a66c1660e5411daf954c5f11910262cb956785473225d797 · Zeichen 17959–20099 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 240 mg concentrate for solution for infusion PREVYMIS 480 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 43–44
HOS-139881 · Präparat HOS-098408
43
Concomitant Effect on concentration† Recommendations concerning co-
medicinal product mean ratio (90% confidence administration with letermovir
interval) for AUC, Cmax
(likely mechanism of action)
etravirine, Interaction not studied. These antivirals may decrease plasma
nevirapine, ritonavir, Expected: concentrations of letermovir.
lopinavir ↓ letermovir Co-administration of letermovir with these
antivirals is not recommended.
(P-gp/UGT induction)
HMG-CoA reductase inhibitors
atorvastatin‡ ↑ atorvastatin Statin-associated adverse events such as
(20 mg single dose)/ AUC 3.29 (2.84, 3.82) myopathy should be closely monitored.
letermovir (480 mg Cmax 2.17 (1.76, 2.67) The dose of atorvastatin should not exceed
daily) 20 mg daily when co-administered with
(CYP3A, OATP1B1/3 letermovir#.
inhibition)
Although not studied, when letermovir is
co-administered with cyclosporine, the
magnitude of the increase in atorvastatin
plasma concentrations is expected to be
greater than with letermovir alone.
When letermovir is co-administered with
cyclosporine, atorvastatin is
contraindicated.
simvastatin, Interaction not studied. Letermovir may substantially increase
pitavastatin, Expected: plasma concentrations of these statins.
rosuvastatin ↑ HMG-CoA reductase Concomitant use is not recommended with
inhibitors letermovir alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) etravirine (HOS-088088) nevirapine (HOS-088064) ritonavir (HOS-084521) cyclosporine (HOS-084512) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage c570e6e7b2698f209a63b48e2fa34a8775afc636122b2479b4d280d87fe30483 · Zeichen 18084–20402 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 20 mg granules in sachet PREVYMIS 120 mg granules in sachet · Abschnitt 4.5 · PDF-Seite 77
HOS-139945 · Präparat HOS-098408
↑ or ↓ efavirenz
(CYP2B6 inhibition or
induction)
etravirine, Interaction not studied. These antivirals may decrease plasma
nevirapine, ritonavir, Expected: concentrations of letermovir.
lopinavir ↓ letermovir Co-administration of letermovir with these
antivirals is not recommended.
(P-gp/UGT induction)
HMG-CoA reductase inhibitors
atorvastatin‡ ↑ atorvastatin Statin-associated adverse events such as
(20 mg single dose)/ AUC 3.29 (2.84, 3.82) myopathy should be closely monitored.
letermovir (480 mg Cmax 2.17 (1.76, 2.67) The dose of atorvastatin should not exceed
daily) 20 mg daily when co-administered with
(CYP3A, OATP1B1/3 letermovir#.
inhibition)
Although not studied, when letermovir is
co-administered with cyclosporine, the
magnitude of the increase in atorvastatin
plasma concentrations is expected to be
greater than with letermovir alone.
When letermovir is co-administered with
cyclosporine, atorvastatin is
contraindicated.
simvastatin, Interaction not studied. Letermovir may substantially increase
pitavastatin, Expected: plasma concentrations of these statins.
rosuvastatin ↑ HMG-CoA reductase Concomitant use is not recommended with
inhibitors letermovir alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) etravirine (HOS-088088) efavirenz (HOS-087947) nevirapine (HOS-088064) ritonavir (HOS-084521) cyclosporine (HOS-084512) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage aff598529ba0f60ca7964d38c6cb34c1b5bd6ad99feccb84070231584d5105b5 · Zeichen 17967–20106 im Abschnitt
Wechselwirkungen · Symkevi
Symkevi 50 mg/75 mg film-coated tablets Symkevi 100 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-140709 · Präparat HOS-098562
Symkevi in combination with ivacaftor has been studied with pitavastatin, an OATP1B1 substrate, and
was found to have no clinically relevant effect on the exposure of pitavastatin (1.24-fold increased
exposure based on AUC). No dose adjustment of OATP1B1 substrates is required when
co-administered with Symkevi.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-08T13:35:00Z · SHA-256 e139cc35dca65a70a96b9c8a1ad8e556657e48aee661616c1f43437d6b315911 · Passage 656b498727eaa83d5268497fd4ec3f5396ea9ce927d4e9c1c8fdc21210a710b6 · Zeichen 4992–5304 im Abschnitt
Wechselwirkungen · Nubeqa
NUBEQA 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-142079 · Präparat HOS-098752
BCRP, OATP1B1 and OATP1B3 substrates
Darolutamide is an inhibitor of breast cancer resistance protein (BCRP) and Organic Anion
Transporting Polypeptides (OATP) 1B1 and 1B3.
Co-administration of rosuvastatin should be avoided unless there is no therapeutic alternative.
Selection of an alternative concomitant medicinal product with less potential to inhibit BCRP,
OATP1B1 and OATP1B3 should be considered.
Administration of darolutamide (600 mg twice daily for 5 days) prior to co-administration of a single
dose of rosuvastatin (5 mg) together with food resulted in approximately 5-fold increase in mean
exposure (AUC) and Cmax of rosuvastatin.
Co-administration of darolutamide with other BCRP substrates should be avoided where possible.
Co-administration of darolutamide may increase the plasma concentrations of other concomitant
BCRP, OATP1B1 and OATP1B3 substrates (e.g. methotrexate, sulfasalazine, fluvastatin, atorvastatin,
pitavastatin). Therefore, it is recommended to monitor patients for adverse reactions of BCRP,
OATP1B1 and OATP1B3 substrates. In addition, the related recommendation in the product
information of these substrates should be followed when co-administered with darolutamide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfasalazine (HOS-089673) atorvastatin (HOS-086304) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) methotrexate (HOS-087522) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-21T11:00:00Z · SHA-256 da13d7ad15d93e78a0008f5eb25e09dc0942552321540cdc62987578c964dccb · Passage b407bc81061cc78c3ae3bac2be182cc0a238ef1a0dedf2d5aad3dc3fec4814ec · Zeichen 2356–3562 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.